These compounds have shown efficacy in pre-clinical studies, and some have entered clinical trials for cancer therapy, with the BCL-2 specific inhibitor venetoclax FDA approved for the treatment of patients with CLL or AML. The gene discussed is BCL2; the disease is acute myeloid leukemia.